Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A.

Objective. The main objective of BCD-085-5/ASTERA study was to prove superiority of NTK over placebo and assess its’ safety in patients with active AS.

Subjects and methods. BCD-085-5/ASTERA was a double-blind, multicenter, randomized, placebo-controlled, phase III study, which included 228 adult patients with active AS, persisting despite active treatment with NSAIDs. AS was considered active at BASDAI score ≥ 4.0. Patients were blindly randomized (1:1) to receive subcutaneous injections of NTK (120 mg) or placebo at weeks 0, 1, 2 and then every other week up to week 14. Starting from week 16 all patients from NTK group and patients from placebo group not achieving ASAS20 were switched to open label 120 mg NTK s/c once every two weeks. The total duration of treatment with NTK was 3 years.

Results. Higher proportion of patients had ASAS40 response at week 16 (primary endpoint) in NTK arm compared to placebo (40,4 vs 2,6%, р <0,0001, 95% CI [27,4%; 48,1%]). Spinal pain subsided and laboratory inflammation markers decreased within one week after the first NTK injection. NTK safety profile was comparable to that of placebo. The most common for NTK adverse events were neutropenia (7,0%) and ALT increase (6,1%).

Conclusion. Subcutaneous NTK at 120 mg dose demonstrated superior efficacy vs placebo, with fast onset of response and favorable safety profile when used in patients with ankylosing spondylitis. 

1. Lapshina SA, Dubinina TV, Badokin VV, et al. Tumor necrosis factor-α inhibitors in the treatment of axial spondyloarthritis, including ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):75-79 (in Russ). doi: 10.14412/1995-4484-2016-1S-75-79

2. Belov BS. Biological therapy and infections in patients with rheumatoid arthritis: relevance and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):322–330. (in Russ). doi: 10.14412/1995-4484-2014-322-330

3. Prado MS, Bendtzen K, Andrade LEC. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. Expert Opin Drug Metab Toxicol. 2017;13(9): 985-95. doi: 10.1080/17425255.2017.1360280.

4. Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13(12):707-18. doi: 10.1038/nrrheum.2017.187

5. Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD Open. 2017;3(1):e000284. doi: 10.1136/rmdopen-2016-000284

6. Cheung PP. Anti-IL17A in Axial Spondyloarthritis-Where Are We At? Front Med (Lausanne). 2017;4:1. doi: 10.3389/fmed.2017.00001

7. Tahir H. Therapies in ankylosing spondylitis-from clinical trials to clinical practice. Rheumatology (Oxford). 2018; 57(suppl6):vi23– vi28. doi:10.1093/rheumatology/key152

8. Van der Heijde D, Cheng-Chu Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16-week results of a phase 3 randomised, double-blind, active-controlled and placebocontrolled trial. Lancet. 2018;392(10163):2441-51. doi: 10.1016/ S0140-6736(18)31946-9

9. Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015;373(26):2534–48. doi:10.1056/NEJMoa1505066

10. Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol Hoboken NJ. 2019;71(4):599–611. doi: 10.1002/art.40753

11. Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–91. doi: 10.1136/annrheumdis-2016-210770

12. Nasonov EL. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)]

13. Torgutalp M, Poddubnyy D. IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opin Biol Ther. 2019;6:1-11. doi: 10.1080/14712598.2019.1605352

14. Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1): 50-55

15. Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;176(3):752-58. doi: 10.1111/bjd.14965

16. Mazurov V, Erdes S, Kunder E, et al. OP0028 Efficacy and safety of BCD-085, a novel il-17 inhibitor, in ankylosing spondylitis. Results of phase 2 clinical study. Ann Rheum Dis. 2018;77(2). doi: 10.1136/annrheumdis-2018-eular.2380

17. Samtsov AV, Khairutdinov VR, Bakulev AA, et al. Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis. Vestnik Dermatologii i Venerologii. 2017;5:52– 63. doi: 10.25208/0042-4609-2017-93-5-52-63

18. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68 (suppl 2): ii1–44. doi: 10.1136/ard.2008.104018

19. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument, Pharmacoeconomics, 1993; 4 (pg. 353-65). doi: 10.2165/00019053-199304050-00006

20. Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016;4:2050312116671725. doi:10.1177/2050312116671725

21. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48(4):1126–36. doi: 10.1002/art.10883

22. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53(5):703-9. doi: 10.1002/art.21445

23. ICH E2A Clinical safety data management: definitions and standards for expedited reporting. 1995

24. Gaidukova IZ, Rebrov AP, Lapshina SA, et al. Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia». Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):474-484 (In Russ.). doi: 10.14412/1995-4484-2017-474-484

25. Cosentyx Assessment report. EMA/CHMP/389874/2014 26. Taltz Assessment report. EMA/59447/2018